ArticleResearch square2025
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer's disease phenotypes in a large mixed dementia cohort.
Katherine Gong, Jigyasha Timsina, Muhammad Ali, Yike Chen, Menghan Liu, Ciyang Wang, Cyril Pottier, Geoffrey K Feld, Gyujin Heo, Tammie L S Benzinger and 9 more
Abstract readPreprint
In one paragraphArticle in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
19 authors.
Katherine GongWashington University School of Medicine.
Jigyasha TimsinaWashington University School of Medicine.
Muhammad AliWashington University School of Medicine.
Yike ChenWashington University School of Medicine.
Menghan LiuWashington University School of Medicine.
Ciyang WangWashington University School of Medicine.
Cyril PottierWashington University School of Medicine.
Geoffrey K FeldGeocyte LLC.
Gyujin HeoWashington University School of Medicine.
Tammie L S BenzingerWashington University School of Medicine.
Cyrus A RajiWashington University School of Medicine.
Beau AncesWashington University.
Brian A GordonWashington University.
Julie K WischWashington University.
Suzanne E SchindlerWashington University School of Medicine.
John C MorrisWashington University School of Medicine.
David M HoltzmanWashington University School of Medicine.
Laura IbanezWashington University School of Medicine.
Carlos CruchagaWashington University School of Medicine.
Funding
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7MUSING QUANTITATIVE TRAITS TO IDENTIFY NOVEL GENES FOR ALZHEIMERS DISEASE AND OTHER COMPLEX TRAITSRF1AG053303 · NIA · WASHINGTON UNIVERSITY · PI CLIMER, SHARLEE, CRUCHAGA, CARLOS · 2016 to 2020
$4.0MGENETIC MODIFIERS OF CEREBROSPINAL FLUID TREM2 IN ALZHEIMER'S DISEASERF1AG058501 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, PICCIO, LAURA · 2018 to 2018
$3.5MThe Familial Alzheimer Sequencing (FASe) ProjectU01AG058922 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, GOATE, ALISON M · 2018 to 2022
$3.5MSex-specific Molecular Profiling to Understand Pathology and Identify Causal Genes and Drug Targets for Alzheimer's DiseaseRF1AG074007 · NIA · WASHINGTON UNIVERSITY · PI SUNG, YUNJU · 2021 to 2021
$2.7MIDENTIFYING RARE VARIANTS THAT INCREASE RISK FOR ALZHEIMER'S DISEASER01AG044546 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS · 2013 to 2017
$2.7MNIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS R01 AG044546NIA NIH HHS RF1 AG053303NIA NIH HHS RF1 AG058501NIA NIH HHS RF1 AG074007NIA NIH HHS U01 AG058922
6 · The paper itselfAbstract
Highly sensitive plasma assays enable accurate blood-based biomarkers for neurodegenerative disease and provide minimally invasive options for clinical use. Large-scale studies encompassing multiple neurodegenerative diseases and utilizing multiplex platforms are essential to uncover disease-specific biomarkers and pathways. We generated and analyzed plasma proteomics using the NULISASeq
Indexed as
CNS protein profilingNeurodegeneration diagnosticsPlasma assaysPlasma-based diagnostics
Identifiers
PMID40678230
PMCPMC12270213
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390